JPWO2019175359A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019175359A5 JPWO2019175359A5 JP2020543213A JP2020543213A JPWO2019175359A5 JP WO2019175359 A5 JPWO2019175359 A5 JP WO2019175359A5 JP 2020543213 A JP2020543213 A JP 2020543213A JP 2020543213 A JP2020543213 A JP 2020543213A JP WO2019175359 A5 JPWO2019175359 A5 JP WO2019175359A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- region
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 41
- 239000000427 antigen Substances 0.000 claims 38
- 102000036639 antigens Human genes 0.000 claims 38
- 108091007433 antigens Proteins 0.000 claims 38
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 6
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 229940127121 immunoconjugate Drugs 0.000 claims 4
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 3
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000031852 Gastrointestinal stromal cancer Diseases 0.000 claims 2
- 101001010819 Homo sapiens Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 2
- 230000001028 anti-proliverative effect Effects 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 210000004602 germ cell Anatomy 0.000 claims 2
- 102000057750 human ERBB3 Human genes 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 101710112752 Cytotoxin Proteins 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 101001037138 Homo sapiens Immunoglobulin heavy variable 3-11 Proteins 0.000 claims 1
- 101001138089 Homo sapiens Immunoglobulin kappa variable 1-39 Proteins 0.000 claims 1
- 102100040222 Immunoglobulin heavy variable 3-11 Human genes 0.000 claims 1
- 102100020910 Immunoglobulin kappa variable 1-39 Human genes 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 241000282560 Macaca mulatta Species 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 1
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 201000002661 Spondylitis Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000026758 coronary atherosclerosis Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000001461 cytolytic effect Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 239000003966 growth inhibitor Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000000578 peripheral nerve Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 201000002511 pituitary cancer Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000001256 tonic effect Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1804094.9 | 2018-03-14 | ||
| GBGB1804094.9A GB201804094D0 (en) | 2018-03-14 | 2018-03-14 | ERBB3 Binding agents |
| PCT/EP2019/056506 WO2019175359A1 (en) | 2018-03-14 | 2019-03-14 | De-immunised anti-erbb3 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021515544A JP2021515544A (ja) | 2021-06-24 |
| JP2021515544A5 JP2021515544A5 (https=) | 2022-05-26 |
| JPWO2019175359A5 true JPWO2019175359A5 (https=) | 2022-05-26 |
Family
ID=61972871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543213A Pending JP2021515544A (ja) | 2018-03-14 | 2019-03-14 | Ｅｒｂｂ３結合剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10975165B2 (https=) |
| EP (1) | EP3765156A1 (https=) |
| JP (1) | JP2021515544A (https=) |
| CN (1) | CN111818972A (https=) |
| AU (1) | AU2019233694A1 (https=) |
| CA (1) | CA3092610A1 (https=) |
| GB (1) | GB201804094D0 (https=) |
| SG (1) | SG11202008513WA (https=) |
| WO (1) | WO2019175359A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11970539B2 (en) * | 2020-09-14 | 2024-04-30 | Ichnos Sciences SA | Antibodies that bind to IL1RAP and uses thereof |
| WO2022078490A1 (zh) * | 2020-10-15 | 2022-04-21 | 上海翰森生物医药科技有限公司 | 抗erbb3抗体或其抗原结合片段及其医药用途 |
| WO2023198138A1 (zh) * | 2022-04-13 | 2023-10-19 | 上海翰森生物医药科技有限公司 | 抗体或其抗原结合片段及其医药用途 |
| TW202432185A (zh) * | 2022-10-28 | 2024-08-16 | 美商翰森生物有限責任公司 | 配體－細胞毒性藥物綴合物及其藥物用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5752687B2 (ja) * | 2009-08-21 | 2015-07-22 | メリマック ファーマシューティカルズ インコーポレーティッド | Ｅｒｂｂ３の外部ドメインに対する抗体およびその使用 |
| CN102884085B (zh) * | 2010-04-09 | 2016-08-03 | Aveo制药公司 | 抗erbb3抗体 |
| EP2630160B1 (en) * | 2010-10-18 | 2016-11-09 | MediaPharma S.r.l. | Erbb3 binding antibody |
| CN105884900A (zh) * | 2011-04-19 | 2016-08-24 | 梅里麦克制药股份有限公司 | 单特异性和双特异性抗igf-1r和抗erbb3抗体 |
| EP2844675B1 (en) * | 2012-05-02 | 2019-01-02 | Symphogen A/S | Humanized pan-her antibody compositions |
| CN105209493B (zh) * | 2013-03-14 | 2019-05-03 | 德克萨斯州大学系统董事会 | 用于诊断和治疗用途的her3特异性单克隆抗体 |
| US10647756B2 (en) * | 2015-05-18 | 2020-05-12 | Pfizer Inc. | Humanized antibodies |
-
2018
- 2018-03-14 GB GBGB1804094.9A patent/GB201804094D0/en not_active Ceased
-
2019
- 2019-03-14 WO PCT/EP2019/056506 patent/WO2019175359A1/en not_active Ceased
- 2019-03-14 CN CN201980017723.3A patent/CN111818972A/zh active Pending
- 2019-03-14 AU AU2019233694A patent/AU2019233694A1/en not_active Abandoned
- 2019-03-14 EP EP19711578.5A patent/EP3765156A1/en not_active Withdrawn
- 2019-03-14 SG SG11202008513WA patent/SG11202008513WA/en unknown
- 2019-03-14 CA CA3092610A patent/CA3092610A1/en active Pending
- 2019-03-14 JP JP2020543213A patent/JP2021515544A/ja active Pending
-
2020
- 2020-07-10 US US16/925,570 patent/US10975165B2/en not_active Expired - Fee Related
-
2021
- 2021-03-02 US US17/189,860 patent/US20210189003A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021519100A5 (https=) | ||
| JPWO2019185717A5 (https=) | ||
| JPWO2019155067A5 (https=) | ||
| JP2025000787A5 (https=) | ||
| JP2021516537A5 (https=) | ||
| JP2021515541A5 (https=) | ||
| JP2020531048A5 (https=) | ||
| RU2020109544A (ru) | Связывающие агенты | |
| JP2021515542A5 (https=) | ||
| JP2021515544A5 (https=) | ||
| JPWO2019224717A5 (https=) | ||
| JP2020514277A5 (https=) | ||
| HRP20250523T1 (hr) | Pd1 i vegfr2 sredstva za dvostruko vezivanje | |
| AU2023200779B2 (en) | TGF-beta-RII binding proteins | |
| RU2019125975A (ru) | Связывающие агенты | |
| RU2019135404A (ru) | Антитела для лечения инфекции гепатитом в и связанных с ней заболеваний | |
| WO2022194257A1 (zh) | 一种喜树碱衍生物的制备方法 | |
| JPWO2019170898A5 (https=) | ||
| JP2021514654A5 (https=) | ||
| JPWO2019175186A5 (https=) | ||
| JPWO2019175359A5 (https=) | ||
| JPWO2019170885A5 (https=) | ||
| JPWO2023143263A5 (https=) | ||
| JPWO2019166596A5 (https=) | ||
| JPWO2021069670A5 (https=) |